## HE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Thomas Specht et al.

Serial No.

09/673,840

Filed

06 March 2001

For

HUMAN NUCLEIC ACID SEQUENCES OF NORMAL BLADDER

TISSUE

## **INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97**

Assistant Commissioner for Patents Washington, D. C. 20231

Sir:

<u>CITED MATERIALS</u>		
Applicant(s) wish to disclose the following information, listed in the attached form PTO-1449.		
	Copies of materials listed but not attached were cited in parent application Serial No.	
	· · · · · · · · · · · · · · · · · · ·	
	Copies of materials listed but not attached were cited in an International Search Report dated 06 March 2000; receipt of any International Search Report and copies of references were confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed 21 November 2001.	
	Copies of materials listed and attached were cited in a communication from a foreign patent office in a counterpart foreign application.	
	Also included are the pending U.S. applications listed below, copies of which are attached:	
<u>FEES</u>		
•	No fee is required for this Information Disclosure Statement because:	
	This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application;	
	This Information Disclosure Statement is being filed before the mailing of a first action on the merits;	
	This Information Disclosure Statement is being filed before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that closes prosecution in the application, and is accompanied by a certification below.	
	A check is attached: This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in §1.17(p).	

	A check is attached: This Information Disclosure Statement is being filed after the mailing date of a notice of allowance under § 1.311 but before the payment of the issue fee and is accompanied by the fee set forth in § 1.17(p) and a certification below.	
<u>CERT</u>	CIFICATION	
	Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.	
	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.	
DEPO	SIT ACCOUNT	
If appropriate, attached is a check in the amount of \$ However, the Commissioner is		
hereby authorized to charge fees under 37 CFR 1.16 and 1.17 which may be required to		
facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are		
attached for this purpose.		
	Respectfully submitted,	
	Yenniter Branigan Registration No.40,921 Patent Agent	
MILLEN, WHI & BRANIGA Arlington Cour 2200 Clarendor Arlington, Virg Telephone: (70 Facsimile: (70	TTE, ZELANO N, P.C. thouse Plaza 1 n Blvd. Suite 1400 inia 22201 03) 243-6333	

Date: 2 January 2002 jjb:K:\ALBRE\5\IDS.doc